Cargando…

4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis

The KRAS mutation is one of the leading driver mutations in colorectal cancer (CRC), and it is usually associated with poor prognosis and drug resistance. Therapies targeting the epidermal growth factor receptor (EFGR) are widely used for end-stage CRC. However, patients with KRAS mutant genes canno...

Descripción completa

Detalles Bibliográficos
Autores principales: Chu, Yi Cheng, Tsai, Tung-Yao, Yadav, Vijesh Kumar, Deng, Li, Huang, Chun-Chih, Tzeng, Yew-Min, Yeh, Chi-Tai, Chen, Ming-Yao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307961/
https://www.ncbi.nlm.nih.gov/pubmed/34299137
http://dx.doi.org/10.3390/ijms22147508
_version_ 1783728167640367104
author Chu, Yi Cheng
Tsai, Tung-Yao
Yadav, Vijesh Kumar
Deng, Li
Huang, Chun-Chih
Tzeng, Yew-Min
Yeh, Chi-Tai
Chen, Ming-Yao
author_facet Chu, Yi Cheng
Tsai, Tung-Yao
Yadav, Vijesh Kumar
Deng, Li
Huang, Chun-Chih
Tzeng, Yew-Min
Yeh, Chi-Tai
Chen, Ming-Yao
author_sort Chu, Yi Cheng
collection PubMed
description The KRAS mutation is one of the leading driver mutations in colorectal cancer (CRC), and it is usually associated with poor prognosis and drug resistance. Therapies targeting the epidermal growth factor receptor (EFGR) are widely used for end-stage CRC. However, patients with KRAS mutant genes cannot benefit from this therapy because of Ras signaling activation by KRAS mutant genes. Our previous study revealed the anti-proliferative effect of 4-acetyl-antroquinonol B (4-AAQB) on CRC cells, but whether the drug is effective in KRAS-mutant CRC remains unknown. We screened CRC cell lines harboring the KRAS mutation, namely G12A, G12C, G12V and G13D, with one wild type cell line as the control; SW1463 and Caco-2 cell lines were used for further experiments. Sulforhodamine B assays, together with the clonogenicity and invasion assay, revealed that KRAS-mutant SW1463 cells were resistant to cetuximab; however, 4-AAQB treatment effectively resensitized CRC cells to cetuximab through the reduction of colony formation, invasion, and tumorsphere generation and of oncogenic KRAS signaling cascade of CRC cells. Thus, inducing cells with 4-AAQB before cetuximab therapy could resensitize KRAS-mutant, but not wild-type, cells to cetuximab. Therefore, we hypothesized that 4-AAQB can inhibit KRAS. In silico analysis of the publicly available GEO (GSE66548) dataset of KRAS-mutated versus KRAS wild-type CRC patients confirmed that miR-193a-3p was significantly downregulated in the former compared with the latter patient population. Overexpression of miR-193a-3p considerably reduced the oncogenicity of both CRC cells. Furthermore, KRAS is a key target of miR-193a-3p. In vivo treatment with the combination of 4-AAQB and cetuximab significantly reduced the tumor burden of a xenograft mice model through the reduction of the expression of oncogenic markers (EGFR) and p-MEK, p-ERK, and c-RAF/p-c-RAF signaling, with the simultaneous induction of miR-193a-3p expression in the plasma. In summary, our findings provide strong evidence regarding the therapeutic effect of 4-AAQB on KRAS-mutant CRC cells. Furthermore, 4-AAQB effectively inhibits Ras singling in CRC cells, through which KRAS-mutant CRC can be resensitized to cetuximab.
format Online
Article
Text
id pubmed-8307961
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83079612021-07-25 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis Chu, Yi Cheng Tsai, Tung-Yao Yadav, Vijesh Kumar Deng, Li Huang, Chun-Chih Tzeng, Yew-Min Yeh, Chi-Tai Chen, Ming-Yao Int J Mol Sci Article The KRAS mutation is one of the leading driver mutations in colorectal cancer (CRC), and it is usually associated with poor prognosis and drug resistance. Therapies targeting the epidermal growth factor receptor (EFGR) are widely used for end-stage CRC. However, patients with KRAS mutant genes cannot benefit from this therapy because of Ras signaling activation by KRAS mutant genes. Our previous study revealed the anti-proliferative effect of 4-acetyl-antroquinonol B (4-AAQB) on CRC cells, but whether the drug is effective in KRAS-mutant CRC remains unknown. We screened CRC cell lines harboring the KRAS mutation, namely G12A, G12C, G12V and G13D, with one wild type cell line as the control; SW1463 and Caco-2 cell lines were used for further experiments. Sulforhodamine B assays, together with the clonogenicity and invasion assay, revealed that KRAS-mutant SW1463 cells were resistant to cetuximab; however, 4-AAQB treatment effectively resensitized CRC cells to cetuximab through the reduction of colony formation, invasion, and tumorsphere generation and of oncogenic KRAS signaling cascade of CRC cells. Thus, inducing cells with 4-AAQB before cetuximab therapy could resensitize KRAS-mutant, but not wild-type, cells to cetuximab. Therefore, we hypothesized that 4-AAQB can inhibit KRAS. In silico analysis of the publicly available GEO (GSE66548) dataset of KRAS-mutated versus KRAS wild-type CRC patients confirmed that miR-193a-3p was significantly downregulated in the former compared with the latter patient population. Overexpression of miR-193a-3p considerably reduced the oncogenicity of both CRC cells. Furthermore, KRAS is a key target of miR-193a-3p. In vivo treatment with the combination of 4-AAQB and cetuximab significantly reduced the tumor burden of a xenograft mice model through the reduction of the expression of oncogenic markers (EGFR) and p-MEK, p-ERK, and c-RAF/p-c-RAF signaling, with the simultaneous induction of miR-193a-3p expression in the plasma. In summary, our findings provide strong evidence regarding the therapeutic effect of 4-AAQB on KRAS-mutant CRC cells. Furthermore, 4-AAQB effectively inhibits Ras singling in CRC cells, through which KRAS-mutant CRC can be resensitized to cetuximab. MDPI 2021-07-14 /pmc/articles/PMC8307961/ /pubmed/34299137 http://dx.doi.org/10.3390/ijms22147508 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chu, Yi Cheng
Tsai, Tung-Yao
Yadav, Vijesh Kumar
Deng, Li
Huang, Chun-Chih
Tzeng, Yew-Min
Yeh, Chi-Tai
Chen, Ming-Yao
4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis
title 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis
title_full 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis
title_fullStr 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis
title_full_unstemmed 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis
title_short 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis
title_sort 4-acetyl-antroquinonol b improves the sensitization of cetuximab on both kras mutant and wild type colorectal cancer by modulating the expression of ras/raf/mir-193a-3p signaling axis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307961/
https://www.ncbi.nlm.nih.gov/pubmed/34299137
http://dx.doi.org/10.3390/ijms22147508
work_keys_str_mv AT chuyicheng 4acetylantroquinonolbimprovesthesensitizationofcetuximabonbothkrasmutantandwildtypecolorectalcancerbymodulatingtheexpressionofrasrafmir193a3psignalingaxis
AT tsaitungyao 4acetylantroquinonolbimprovesthesensitizationofcetuximabonbothkrasmutantandwildtypecolorectalcancerbymodulatingtheexpressionofrasrafmir193a3psignalingaxis
AT yadavvijeshkumar 4acetylantroquinonolbimprovesthesensitizationofcetuximabonbothkrasmutantandwildtypecolorectalcancerbymodulatingtheexpressionofrasrafmir193a3psignalingaxis
AT dengli 4acetylantroquinonolbimprovesthesensitizationofcetuximabonbothkrasmutantandwildtypecolorectalcancerbymodulatingtheexpressionofrasrafmir193a3psignalingaxis
AT huangchunchih 4acetylantroquinonolbimprovesthesensitizationofcetuximabonbothkrasmutantandwildtypecolorectalcancerbymodulatingtheexpressionofrasrafmir193a3psignalingaxis
AT tzengyewmin 4acetylantroquinonolbimprovesthesensitizationofcetuximabonbothkrasmutantandwildtypecolorectalcancerbymodulatingtheexpressionofrasrafmir193a3psignalingaxis
AT yehchitai 4acetylantroquinonolbimprovesthesensitizationofcetuximabonbothkrasmutantandwildtypecolorectalcancerbymodulatingtheexpressionofrasrafmir193a3psignalingaxis
AT chenmingyao 4acetylantroquinonolbimprovesthesensitizationofcetuximabonbothkrasmutantandwildtypecolorectalcancerbymodulatingtheexpressionofrasrafmir193a3psignalingaxis